LXRX
Lexicon Pharmaceuticals, Inc.
There isn't enough reported data to score LXRX yet.
LXRX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
LXRX's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
LXRX PE Valuation
LXRX has no meaningful PE right now: it lost money over the past year.
LXRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect LXRX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LXRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.14 | +$0.04 |
| Q2 2026 | -$0.15 | +$0.17 |
| Q1 2026 | -$0.07 | +$0.43 |
| Q4 2025 | -$0.14 | +$0.49 |
| Q3 2025 | -$0.18 | +$0.57 |
| Q2 2025 | -$0.32 | +$0.46 |
| Q1 2025 | -$0.50 | +$0.33 |
| Q4 2024 | -$0.63 | +$0.17 |
LXRX is still losing money, but far less than before: $0.14 per share over the past year, against $1.05 at its worst in late 2020.
LXRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.3M | -21% |
| Q2 2026 | $692K | -98% |
| Q1 2026 | $21.1M | +1572% |
| Q4 2025 | $5.5M | -79% |
| Q3 2025 | $14.2M | +710% |
| Q2 2025 | $28.9M | +1653% |
| Q1 2025 | $1.3M | +12% |
| Q4 2024 | $26.6M | +3683% |
LXRX's revenue has slid since its 2025 peak: $11M last quarter, down 21% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -129% | -43 points |
| Q2 2026 | -3835% | -3848 points |
| Q1 2026 | -4.7% | +2030 points |
| Q4 2025 | -269% | -146 points |
| Q3 2025 | -86% | +3554 points |
| Q2 2025 | 13% | +3374 points |
| Q1 2025 | -2035% | +1977 points |
| Q4 2024 | -123% | +6534 points |
LXRX's operating margin was −129% last quarter, down 43 points from the same quarter a year ago.
LXRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$8.1M | +$15.8M |
| Q1 2026 | -$14.7M | +$29M |
| Q4 2025 | -$17.2M | +$4.7M |
| Q3 2025 | -$23.8M | +$30.1M |
| Q1 2025 | -$43.8M | +$11.4M |
| Q4 2024 | -$22M | +$28.6M |
| Q3 2024 | -$53.9M | -$12.2M |
| Q2 2024 | -$48.8M | -$10.5M |
LXRX has burned cash in almost every quarter: −$49M over the past year, against −$144M the year before.
LXRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +7.3M shares |
| 1 year | +22% | +81.6M shares |
| 3 years | +82% | +200M shares |
| 5 years | +205% | +299M shares |
| Available history | +319% | +339M shares |
LXRX has 445M diluted shares, up 22% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | $1.7M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $824,000 |
LXRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2021 | -1.8x | Net Cash |
| Q1 2020 | 1.9x | Healthy |
| Q4 2019 | 1.4x | Healthy |
LXRX has more cash than debt.
LXRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.4 | Neutral |
| Stochastic | 27.1 | Neutral |
LXRX's weekly RSI is 48 (neutral) and its Stochastic is 27 (neutral).
LXRX PE vs Healthcare Sector
| Metric | LXRX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
LXRX has no meaningful PE right now: it lost money over the past year.
LXRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.66 | 9.6% above |
| 20 week MA | $2.02 | 9.9% below |
| 50 week MA | $1.79 | 1.7% above |
| 100 week MA | $1.36 | 34% above |
| 200 week MA | $1.61 | 13% above |
LXRX's trend is mixed: it's above four of its five weekly moving averages, and 13% above its 200-week average.
LXRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.26 | $3.49 | -18% |
| 2021 | $3.49 | $4.36 | +25% |
| 2022 | $4.36 | $1.95 | -55% |
| 2023 | $1.95 | $1.53 | -22% |
| 2024 | $1.53 | $0.77 | -50% |
| 2025 | $0.77 | $1.23 | +60% |
| 2026 YTD | $1.23 | $1.82 | +48% |
LXRX is up 48% so far in 2026, after finishing lower in four of the previous six years.